Genenta Science Secures Up to €20M Financing
Ticker: GNTA · Form: 6-K · Filed: Mar 19, 2025 · CIK: 1838716
| Field | Detail |
|---|---|
| Company | Genenta Science S.P.A. (GNTA) |
| Form Type | 6-K |
| Filed Date | Mar 19, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: financing, convertible-bond, healthcare
TL;DR
Genenta Science gets €20M convertible bond from ETB.
AI Summary
On March 19, 2025, Genenta Science S.p.A. announced a financing agreement for up to €20 million. This funding will be provided by ENEA Tech and Biomedical (ETB) through the issuance of a mandatory convertible bond.
Why It Matters
This financing provides Genenta Science with significant capital to advance its operations and potentially its pipeline of therapeutic candidates.
Risk Assessment
Risk Level: medium — The company is issuing a mandatory convertible bond, which introduces potential dilution and debt-like characteristics.
Key Numbers
- €20 million — Financing (Total potential funding from ETB)
Key Players & Entities
- Genenta Science S.p.A. (company) — Registrant
- €20 million (dollar_amount) — Financing amount
- March 19, 2025 (date) — Announcement date
- ENEA Tech and Biomedical (ETB) (company) — Financing provider
FAQ
What is the nature of the financing agreement?
Genenta Science S.p.A. announced a financing of up to €20 million through the issuance of a mandatory convertible bond to ENEA Tech and Biomedical (ETB).
Who is providing the financing?
The financing is being provided by ENEA Tech and Biomedical (ETB), described as a leading private foundation.
When was this financing announced?
The announcement was made on March 19, 2025.
What type of financial instrument is being used for the financing?
A mandatory convertible bond is being issued by Genenta Science S.p.A. to ETB.
What is the maximum amount Genenta Science S.p.A. can receive from this financing?
Genenta Science S.p.A. can receive up to €20 million from this financing.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 19, 2025 regarding Genenta Science S.p.A. (GNTA).